Compare Repligen Corporation Common Stock (RGEN) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vanguard Ultra Short Bond ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B), while Vanguard Ultra Short Bond ETF trades at $49.48 (market cap $10.20B). The key difference: Repligen Corporation Common Stock and Vanguard Ultra Short Bond ETF are close in size by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vanguard Ultra Short Bond ETF for 64 Days on average.
| RGEN | VUSB | |
|---|---|---|
Market Cap | $11.31B | $10.20B |
Volume | 1,216,919 | 1,909,366 |
Sector | Health | Leveraged / Inverse |
52-Week High | $194.57 | $50.03 |
52-Week Low | $102.87 | $49.41 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $11.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VUSB is trading at $49.475, showing minimal daily movement with a slight decline of 0.01%. Technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The ETF maintains consistent dividend distributions, with recent payments of $0.17-0.18 per share. Market sentiment is influenced by Federal Reserve interest rate expectations, positioning short-term bond ETFs favorably amid potential rate increases.
The outlook for VUSB remains cautious due to bearish technical signals and interest rate sensitivity. Investment opportunity exists for investors seeking short-term bond exposure with regular income, though risks include Fed policy shifts and market volatility. The ETF's stability and dividend consistency provide defensive characteristics in uncertain rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
